3 recruiting, 2 completed, 1 withdrawn. 4 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Epithelial Tumors, Malignant: new trials by email Literature Review of Epithelial Tumors, Malignant trials Research Report on Epithelial Tumors, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors [68Ga]Ga-PN-EpC1 PET/CT - Epithelial Tumors, Malignant | Not applicable | Recruiting | Peking University People's Hospital | 30 | 2026-03-04 | 2026-03-30 |
| Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin - Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe) | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2024-01-31 | 2024-02-02 | |
| Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors MT-302 (A) - Epithelial Tumors, Malignant | Phase 1 | Recruiting | Myeloid Therapeutics | 48 | 2023-08-02 | 2024-01-18 |
| Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen, Interleukin-2 - Epithelial Tumors, Malignant, Malignant Solid Tumor | Early Phase 1 | Recruiting | Vall d'Hebron Institute of Oncology | 10 | 2021-10-28 | 2024-11-07 |
| NHS-IL12 for Solid Tumors NHS-IL-12 - Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant | Phase 1 | Completed | National Cancer Institute (NCI) | 72 | 2011-12-12 | 2021-10-18 |
| A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors MEHD7945A - Epithelial Tumors, Malignant | Phase 1 | Completed | Genentech, Inc. | 66 | 2010-11-09 | 2018-05-01 |
Carcinoma (6) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Malignant mesenchymal tumor (1) · Mesothelioma, Malignant (1) · Myeloproliferative Disorder, Chronic, with Eosinophilia (1) · Pleural Effusion, Malignant (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1)
Clinical Protocols (1) · Cyclophosphamide (1) · Cytoreduction Surgical Procedures (1) · Interleukin-2 (1) · LMB-100 (1) · MEHD7945A (1) · NHS-IL12 immunocytokine (1) · aldesleukin (1) · fludarabine (1)
National Cancer Institute (NCI) (2) · Genentech, Inc. (1) · Myeloid Therapeutics (1) · Peking University People's Hospital (1) · Vall d'Hebron Institute of Oncology (1)
United States (3) · Spain (2) · Australia (1) · China (1)
Andrea Pirzkall, M.D. (1) · David S Schrump, M.D. (1) · Elena Garralda (1) · James L Gulley, M.D. (1) · Matthew Maurer, MD (1)